Colorectal cancer cohort study (COLO-COHORT)

Not Applicable

• Conditions: Colorectal neoplasia; Colorectal neoplasia, colorectal cancer; Cancer

• Registration Number: ISRCTN17473023
• Lead Sponsor: South Tyneside and Sunderland NHS Foundation Trust

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2019-12-23
• Last Update Posted: 9 September 2024
• Study Completion: 2036-01-14

Recruitment & Eligibility

• Status: Ongoing
• Sex: All
• Target Recruitment: 15000

Inclusion Criteria

Group A:
1. Aged =30 years and able to give informed consent
2. Patients attending colonoscopy:
2.1 Through Bowel Cancer Screening Programme (FIT positive, Bowelscope conversion, surveillance)
2.2 Through standard NHS care (most commonly due to iron deficiency anaemia, altered bowel habit, weight loss, rectal bleeding, planned polypectomy, those referred on basis of family history, abnormal cross-sectional imaging, polyp surveillance or post CRC surveillance)

(COLO-SPEED) Group B:
1. Any patient attending for colonoscopy and able to give informed consent
2. At least 18 years old
3. In a centre supported by COLO-SPEED infrastructure (i.e. in North of England)

Exclusion Criteria

Group A:
1. Unable to give informed consent
2. Known polyposis syndrome
3. Previous total colectomy
4. Known colonic stricture which would limit complete colonoscopy
5. Attending for planned therapeutic procedure other than polypectomy, such as insertion of colonic stent
6. Attending for assessment of known inflammatory bowel disease (IBD) activity or for IBD surveillance
7. Patients currently recruited into an interventional CTIMP for CRC prevention

COLO-SPEED (Group B):
1. DOes not meet inclusion criteria

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The occurrence of colorectal neoplasia (colorectal cancer and advanced adenomas), measured by reviewing patient endoscopy reports, blood results, and health questionnaire. These will be analysed via logistic regression and subsequent structural equation modelling. Timepoint: baseline

Secondary Outcome Measures

Name	Time	Method
Stool microbiome in different patient subgroups (i.e., normal colon, adenomas, bowel cancer), measured by reviewing stool samples at baseline